

# **Disclosures**

## Personal Commercial (15)

| Company Name                                 | Relationship Category  | Compensation Level       | Topic Area(s)                      |
|--|--|--------------------------|------------------------------------|
| Self   |  |                          |                                    |
| Amgen  | Consultant Fees/Honoraria  | Significant (>= \$5,000) | General Cardiology                 |
| Astra Zeneca                                 | Consultant Fees/Honoraria  | Significant (>= \$5,000) | General Cardiology                 |
| Cytokinetics                                 | Consultant Fees/Honoraria  | Significant (>= \$5,000) | General Cardiology                 |
| Eli Lilly and Company                        | Other - Compensation for clinical endpoint adjudication activities | Significant (>= \$5,000) | Other                              |
| Elsevier Publishers                          | Consultant Fees/Honoraria  | Significant (>= \$5,000) | General Cardiology                 |
| Familial Hypercholesterolemia Foundation     | Research/Research Grants   | Significant (>= \$5,000) | Prevention                         |
| Ferring Pharmaceuticals                      | Research/Research Grants   | Significant (>= \$5,000) | General Cardiology                 |
| Janssen Pharmaceuticals                      | Consultant Fees/Honoraria  | Significant (>= \$5,000) | General Cardiology Other           |
| Myokardia                                    | Research/Research Grants   | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies |
| Novo Nordisk Inc.                            | Other - Compensation for clinical endpoint adjudication activities | Significant (>= \$5,000) | General Cardiology                 |
| Patient Centered Outcomes Research Institute | Research/Research Grants   | Significant (>= \$5,000) | General Cardiology                 |
| Regeneron                                    | Data Safety Monitoring Board                                       | Modest (< \$5,000)       | General Cardiology                 |
| Roche-Genetech                               | Data Safety Monitoring Board                                       | Modest (< \$5,000)       | General Cardiology                 |
| Sanofi-Aventis                               | Research/Research Grants   | Significant (>= \$5,000) | General Cardiology                 |
| Signal Path                                  | Consultant Fees/Honoraria  | Significant (>= \$5,000) | General Cardiology                 |
|  |  |                          |                                    |

# Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

# Personal Organizational or Other Non-Commercial (0)

No disclosures on record

## Clinical Trial Enroller (0)

No disclosures on record

# Institutional Financial Decision-Making Role (0)

No disclosures on record

# Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

# Agreement

## Certified Education Attestation | Signed on 10/29/2019

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement in the properties of the

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/29/2019

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureand Assignment Agreement

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

# On-Going Obligation Agreement | Signed on 10/29/2019

#### **ACC** and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.